Detailed information for compound 1984399

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 530.017 | Formula: C29H28ClN5O3
  • H donors: 3 H acceptors: 4 LogP: 5.02 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 2
  • SMILES: COc1cc(cc(c1O)Cl)c1ccc2c(c1)c(Nc1ccc(nc1)N1CCNCC1)c(cn2)C(=O)C1CC1
  • InChi: 1S/C29H28ClN5O3/c1-38-25-14-19(13-23(30)29(25)37)18-4-6-24-21(12-18)27(22(16-32-24)28(36)17-2-3-17)34-20-5-7-26(33-15-20)35-10-8-31-9-11-35/h4-7,12-17,31,37H,2-3,8-11H2,1H3,(H,32,34)
  • InChiKey: RPNAFEOUPITPAI-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens maternal embryonic leucine zipper kinase Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Trichomonas vaginalis CAMK family protein kinase Get druggable targets OG5_133787 All targets in OG5_133787
Echinococcus granulosus maternal embryonic leucine zipper kinase Get druggable targets OG5_133787 All targets in OG5_133787
Trichomonas vaginalis CAMK family protein kinase Get druggable targets OG5_133787 All targets in OG5_133787
Echinococcus multilocularis maternal embryonic leucine zipper kinase Get druggable targets OG5_133787 All targets in OG5_133787
Brugia malayi Protein kinase domain containing protein Get druggable targets OG5_133787 All targets in OG5_133787
Schistosoma japonicum gsx family homeobox protein; serine/threonine kinase Get druggable targets OG5_133787 All targets in OG5_133787
Schistosoma mansoni serine/threonine kinase Get druggable targets OG5_133787 All targets in OG5_133787
Trichomonas vaginalis CAMK family protein kinase Get druggable targets OG5_133787 All targets in OG5_133787
Schistosoma japonicum ko:K08799 maternal embryonic leucine zipper kinase, putative Get druggable targets OG5_133787 All targets in OG5_133787
Loa Loa (eye worm) CAMK/CAMKL/MELK protein kinase Get druggable targets OG5_133787 All targets in OG5_133787

By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Schistosoma mansoni serine/threonine kinase 0.015 0.1362 0.1362
Brugia malayi hypothetical protein 0.0291 0.3309 0.2254
Echinococcus multilocularis MAP kinase activated protein kinase 2 0.0775 1 1
Echinococcus granulosus maternal embryonic leucine zipper kinase 0.0101 0.0686 0.0686
Loa Loa (eye worm) CAMK/CAMKL/MELK protein kinase 0.015 0.1362 0.0411
Echinococcus granulosus MAP kinase activated protein kinase 2 0.0775 1 1
Echinococcus multilocularis maternal embryonic leucine zipper kinase 0.0101 0.0686 0.0686
Loa Loa (eye worm) camk/mapkapk/mapkapk protein kinase 0.0775 1 1
Trichomonas vaginalis CAMK family protein kinase 0.015 0.1362 1
Schistosoma mansoni serine/threonine protein kinase 0.0775 1 1

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 3.8 nM BindingDB_Patents: Kinase Assay. MELK activity was determined in the presence or absence of compounds using fluorescein isothiocyanate-labeled (FITC-labeled) histone H3 peptide as a substrate. The extent of FITC-labeled histone H3 peptide phosphorylation was measured by immobilized metal ion affinity-based fluorescence polarization (IMAP) technology (Sportsman J R, et al., Assay Drug Dev. Technol. 2: 205-14, 2004) using IMAP FP Progressive Binding System (Molecular Devices Corporation). Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%. The serially diluted compounds, 0.8 ng/micro-L PBK (Carna Biosciences) and 100 nM FITC-labeled histone H3 peptide were reacted in a reaction buffer (20 mM HEPES, 0.01% Tween-20, 0.3 mM MgCl2, 2 mM dithiothreitol, 50 micro-M ATP, pH 7.4) at room temperature for 1 hour. The reaction was stopped by the addition of three fold assay volume of progressive binding solution. Following 0.5 hour incubation at room temperature. ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.